BHCM
CSTL icon

Brevan Howard Capital Management’s Castle Biosciences CSTL Stock Holding History

Brevan Howard Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,560
Closed -$456K – 2161
2026
Q1 		$456K Buy
+18,560
New +$608K ﹤0.01% 1355
2025
Q4 		– Sell
-19,128
Closed -$436K – 1892
2025
Q3 		$436K Sell
19,128
-22,173
-54% -$450K ﹤0.01% 1357
2025
Q2 		$843K Buy
41,301
+29,096
+238% +$539K ﹤0.01% 1142
2025
Q1 		$244K Buy
+12,205
New +$302K ﹤0.01% 924
2024
Q4 		– Sell
-10,622
Closed -$303K – 1109
2024
Q3 		$303K Buy
+10,622
New +$270K ﹤0.01% 855

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's CSTL Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 18,560 shares — an estimated $456K sold.

Brevan Howard Capital Management first reported a position in CSTL in Q3 2024 and held it in 5 quarters. The position peaked at $843K in Q2 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 18,560 Castle Biosciences shares in Q2 2026, an estimated $456K.
  • Brevan Howard Capital Management first reported a position in Castle Biosciences in Q3 2024 and held it in 5 quarters.
  • Brevan Howard Capital Management's Castle Biosciences position peaked at $843K in Q2 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.